Use of CD36 to identify cancer subjects for treatment

Patent metadata

Field	Value
Publication number	US-10175243-B2
Application number	US-201715684639-A
Country	US
Kind code	B2
Filing date	Aug 23, 2017
Priority date	Mar 14, 2013
Publication date	Jan 8, 2019
Grant date	Jan 8, 2019

Abstract

Provided herein are methods for identifying a subject with cancer for treatment with a Psap peptides. The subject is identified based on a level of CD36. Also provided herein are compositions and methods for treatment of a subject with cancer based on a level of CD36.

First claim

What is claimed is:

1. A method for treating cancer in a subject in need thereof, the method comprising: administering to the subject an effective amount of a prosaposin (Psap) peptide, wherein the cancer is characterized by an elevated level of CD36 as compared to a control level of CD36, and wherein the Psap peptide is 4 to 9 amino acids in length and comprises an amino acid sequence selected from the group consisting of CDWLPK (SEQ ID NO: 1), DWLPK (SEQ ID NO: 2), DWLP (SEQ ID NO: 3), and amino acid substitution variants thereof, wherein the amino acid substitution variant comprises an amino acid substitution selected from the group consisting of:
a) Tyrosine (Y) for Tryptophan (W);
b) an amino acid substitution for Leucine (L) selected from Valine (V), Alanine (A) or Glycine (G), or a non-canonical amino acid selected from the group consisting of methylvaline, methylleucine, or sarcosine;
c) Arginine (R) for Lysine (K);
d) a D-isomer of Aspartic Acid (D) for an L-isomer of Aspartic Acid (D) and/or a D-isomer of Leucine (L) for a L-isomer of Leucine (L); and
e) a D-isomer of Tryptophan (W) for an L-isomer of Tryptophan (W) and/or a D-isomer of Proline (P) for an L-isomer of Proline (P).

2. The method of claim 1 , wherein the control level is a level of CD36 from a non-cancerous cell or tissue obtained from the subject having the cancer.

3. The method of claim 1 , wherein the control level is a level of CD36 in a cell or tissue obtained from a healthy subject or a population of healthy subjects.

4. The method of claim 1 , wherein the control level is a predetermined level.

5. The method of claim 1 , wherein the level of CD36 is a CD36 protein level.

6. The method of claim 1 , wherein the cancer is prostate cancer, breast cancer, ovarian cancer, lung cancer, leukemia, pancreatic cancer, glioblastoma multiforme, astrocytoma, or melanoma.

7. The method of claim 1 , wherein the Psap peptide is a cyclic peptide.

8. The method of claim 1 , wherein the control level is a level of CD36 from a non-cancerous cell or tissue obtained from the subject having the cancer.

9. The method of claim 1 , wherein the Psap peptide comprises one or more modifications selected from the group consisting of acetylation, pegylation, and conjugation to a polymer that enhances serum half-life of the peptide.

10. The method of claim 1 , wherein the Psap peptide is a dimer, trimer, or multimer.

11. The method of claim 1 , wherein the Psap peptide is 6 or fewer amino acids in length.

Assignees

• Childrens Medical Center

Inventors

• Watnick Randolph S

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P35/02

  specific for leukemia · CPC title

• C12Q1/6886

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• G01N2800/52

  Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis · CPC title

• G01N2333/70596

  Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705 · CPC title